C
Overview
CSBio designs and manufactures peptide synthesis equipment and provides peptide production services. It offers automated peptide synthesizers along with custom and cGMP peptides for the global pharmaceutical industry. The company differentiates itself with 30+ years in the field, a Silicon Valley base, and an integrated offering that covers both equipment and manufacturing with GMP/GMP-like compliance and global reach. Its goal is to support drug development and production by delivering reliable, scalable peptide synthesis solutions and regulatory-compliant processes.
Work here?Claim your company
Simplify's take
What believers are saying
- CSBio showcased at TIDES Europe in Amsterdam, November 2026, strengthening buyer visibility.
- CSBio’s October 2026 content tracks GLP-1, oral peptides, and radioligands, expanding demand.
- CSBio’s Q3 2026 updates signal active marketing across a fast-growing peptide-capex cycle.
What critics are saying
- Bruker, CEM, and Chinese low-cost rivals pressure CSBio’s instrument margins in 2026.
- CSBio’s private, capital-light profile hides funding stress and constrains rapid product expansion.
- A peptide instrument downturn would hit CSBio’s entire business before recurring revenue exists.
What makes CSBio unique
- CSBio sells peptide and oligonucleotide synthesizers from research through commercial scale.
- CSBio claims the world’s highest pilot- and commercial-scale peptide synthesizer sales, November 2026.
- CSBio launched the CS136M six-vessel automated research synthesizer on October 26, 2026.
Help us improve and share your feedback! Did you find this helpful?